Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Women with advanced ovarian cancer will not receive the first life-extending drug in 15 years to treat the disease after the NHS rationing body said that its potential benefits did not outweigh its high cost.
New draft guidance issued by the National Institute for Health and Clinical Excellence (Nice) means that Avastin will not be available on the NHS in cases where advanced ovarian cancer has returned at least six months after the woman has undergone platinum-based chemotherapy.
"In this instance the appraisal committee concluded that, although bevacizumab [Avastin] may help to delay the spread of a patient's cancer for a limited time, the evidence did not show that bevacizumab justifies its very high cost and could not be recommended", said Sir Andrew Dillon, Nice's chief executive.
http://www.guardian.co.uk/society/2013/feb/01/nhs-refuses-drug-women-cancer
New draft guidance issued by the National Institute for Health and Clinical Excellence (Nice) means that Avastin will not be available on the NHS in cases where advanced ovarian cancer has returned at least six months after the woman has undergone platinum-based chemotherapy.
"In this instance the appraisal committee concluded that, although bevacizumab [Avastin] may help to delay the spread of a patient's cancer for a limited time, the evidence did not show that bevacizumab justifies its very high cost and could not be recommended", said Sir Andrew Dillon, Nice's chief executive.
http://www.guardian.co.uk/society/2013/feb/01/nhs-refuses-drug-women-cancer